➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Express Scripts
Harvard Business School
Baxter
Colorcon

Last Updated: October 20, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,629,828

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,629,828 protect, and when does it expire?

Patent 9,629,828 protects XIFAXAN and is included in one NDA.

This patent has forty-five patent family members in twenty countries.

Summary for Patent: 9,629,828
Title:Methods of treating traveler's diarrhea and hepatic encephalopathy
Abstract: Treatment of traveler's diarrhea using in subjects having hepatic encephalopathy using gastrointestinal specific antibiotics is disclosed. One example of a gastrointestinal specific antibiotic is rifaximin.
Inventor(s): Forbes; William (Raleigh, NC), Bortey; Enoch (Chapel Hill, NC)
Assignee: Salix Pharmaceuticals, Ltd. (Bridgewater, NJ)
Application Number:14/605,109
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,629,828
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 9,629,828

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 022554-001 Mar 24, 2010 RX Yes Yes   Start Trial   Start Trial REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) IN ADULTS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,629,828

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009298389   Start Trial
Australia 2010260089   Start Trial
Australia 2010271070   Start Trial
Brazil PI0920465   Start Trial
Brazil PI1010028   Start Trial
Canada 2739436   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
McKinsey
Colorcon
Dow
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.